NCT07301892 Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis
| NCT ID | NCT07301892 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
| Condition | Rheumatoid Arthritis (RA |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-10-01 with a primary completion date of 2026-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Generative AI (GenAI) based on large language models (LLMs) is expected to improve the diagnosis and treatment of autoimmune diseases. We are studying how GenAI may affect the diagnosis of various complications of rheumatoid arthritis (RA). In a retrospective study using RA patients' EHR records, we will quantify physician adoption of GenAI predictions for RA complications and co-existing diseases. In a prospective observational study, we will assess the feasibility of using GenAI predictions as additional clinical information to help physicians make more complete diagnoses of RA complications and co-existing diseases, including complex, uncommon, or rare conditions.
Eligibility Criteria
Inclusion Criteria: * Patients with an initial diagnosis of rheumatoid arthritis (RA). * All real-world RA inpatients admitted to our department. * Admission occurring within the real-world data study period. Exclusion Criteria: * Patients subsequently confirmed not to have RA during the study.
Contact & Investigator
Quan Jiang Guang'anmen Hospital, China Academy of Chinese Medical Science
✉ doctorjq@126.com📞 010-88001942
Frequently Asked Questions
Who can join the NCT07301892 clinical trial?
This trial is open to participants of all sexes, studying Rheumatoid Arthritis (RA. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07301892 currently recruiting?
Yes, NCT07301892 is actively recruiting participants. Contact the research team at doctorjq@126.com for enrollment information.
Where is the NCT07301892 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07301892 clinical trial?
NCT07301892 is sponsored by Guang'anmen Hospital of China Academy of Chinese Medical Sciences. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.